Kerydin, a nail infection drug owned by ANACOR, has been approved by FDA

Source: Ding Xiangyuan, July 10, 2014, ANACOR pharmaceutical company, said that the US Food and Drug Administration approved its drug kerydin for the treatment of toenail fungal infection Kerydin is a liquid for external use and is expected to be available in the US as early as this quarter, the company said on July 8 A month ago, the drug jublia of Valeant international, a Canadian pharmaceutical company, was approved in the United States ANACOR's share price fell nearly 11% in early trading on July 8 Last year, kerydin's stock plummeted after effective trial data showed it was less effective than jublia's The goal of the two drugs is the same: to "cure it all" so that there is no trace of fungal infection in the nail Among them, the most common nail infection is gray nails, with a high recurrence rate Analysts at wedbush, a securities firm, forecast the drug's U.S sales of $16 million next year, reaching a peak of $347 million by 2021 According to ANACOR, gray nails can cause nails to deform, discolor and separate nail beds, affecting about 350000 people in the United States ANACOR, based in Palo Alto, California, recovered some of its losses later in the morning, down 7% to $15.59.